ACE and heart failure: Included factors in the model were the type of cardiomyopathy (ischemic vs. non-ischemic), the wearing time of the WCD in hours, the length of duration the WCD was carried in days and the initiation of each of the guideline recommended heart failure medications (B-Blockers, Angiotensin Converting Enzyme (ACE)-Inhibitors, Angiotensin-1 (AT-1) receptor blockers, Sacubitril/Valsartan, Mineralcorticoid Receptor Antagonists (MRAs) and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (Table 3).